AARD vs REGN: Which Stock is Better?

Side-by-side comparison of Aardvark Therapeutics Inc and Regeneron Pharmaceuticals Inc in 2026

Comparison Updated:

AARD

Aardvark Therapeutics Inc

$15.52

REGN

Regeneron Pharmaceuticals Inc

$733.78

Key Metrics Comparison

MetricAARDREGNWinner
Market Cap$334.66M$77.77BREGN
P/E RatioN/A17.58REGN
EPS (TTM)$N/A$41.75REGN
Revenue Growth0.0%0.0%REGN
Gross Margin0.0%45.8%REGN

Analyze AARD

Full quant analysis

Analyze REGN

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is AARD or REGN a better investment?

Comparing AARD and REGN: Aardvark Therapeutics Inc has a market cap of $334.66M while Regeneron Pharmaceuticals Inc has $77.77B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between AARD and REGN?

AARD (Aardvark Therapeutics Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: AARD or REGN?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: AARD or REGN?

REGN has higher revenue growth at 0.0% vs 0.0% for AARD.

Which company is more profitable: AARD or REGN?

Regeneron Pharmaceuticals Inc (REGN) has higher gross margins at 45.8% compared to 0.0% for AARD.

Which is the larger company: AARD or REGN?

Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $77.77B compared to $334.66M for AARD.

Should I buy AARD or REGN in 2026?

Both AARD and REGN have investment merit. AARD trades at $15.52 while REGN trades at $733.78. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between AARD and REGN stock?

Key differences: Market Cap ($334.66M vs $77.77B), P/E Ratio (N/A vs 17.6x), Revenue Growth (0.0% vs 0.0%), Gross Margin (0.0% vs 45.8%).

Popular Stock Comparisons